Sandramycin analogs
CA 2285259 A1 · Owner: Boger, Dale L. · Inventors: Boger, Dale L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Analogs of sandramycin (1) are synthesized and shown to have cytoxic activity against various tumor cell types. The relative cytotoxic properties of the sandramycin analogs are approximately parallel to their relative DNA binding affinities. An exception to this generalization is compound (4) which completely lacks the sandramycin chromophore phenol. Although typically 4-10x less potent than sandramycin against leukemia cell lines compound (4) proved , to be 1-10,000x more potent against melanomas carcinomas, and adenocarcinomas , exhibiting IC50 values of 1 pM-10 nM. This activity places compound (4) among the most potent agents identified to date.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 27, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 27, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 27, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.